HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $50 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Amylyx Pharma (NASDAQ:AMLX) and maintained a $50 price target.
July 27, 2023 | 10:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amylyx Pharma's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $50 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and a maintained price target of $50 by HC Wainwright & Co. suggests a positive outlook for Amylyx Pharma, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100